A promising AIDS vaccine developed by Merck has proven unsuccessful in a major international trial. It’s a huge setback, not just because this particular vaccine was further along than others, but because it used a new strategy shared by a number of alternatives.
Merck raised suspicions about its cancer-fighting HPV vaccine with a cluelessly aggressive lobbying campaign, but a lifesaving drug is still a lifesaving drug.